Arcutis Biotherapeutics, Inc. (ARQT) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-04-03

Key Insights

Insider Howard G. Welgus sold 10,000 shares of Arcutis Biotherapeutics (ARQT) on April 1, 2026, reducing his direct ownership to 39,744 shares.
The sale was made pursuant to a 10b5-1 trading plan adopted on March 11, 2025, indicating a pre-planned transaction rather than an opportunistic sale.
The sale price of $23.88 per share was within a range of $23.61 to $24.12, suggesting the transaction was executed at market prices.

Want the newest filings?

This analysis covers the filing from 2026-04-03. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-01-07

The reporting person, Patrick Burnett, an executive at Arcutis Biotherapeutics, Inc. (ARQT), sold 2,490 shares of the company's common stock on January 5, 2026, at a weighted average price of $28.9822 per share.
The sale was executed pursuant to a 10b5-1 trading plan that was adopted on December 12, 2024, indicating a pre-planned transaction.
After the reported transaction, the reporting person still holds 94,120 shares of the company's common stock, indicating they maintain a significant ownership position.

Filed: 2026-01-06

The reporting person, Howard G. Welgus, sold 10,000 shares of Arcutis Biotherapeutics, Inc. (ARQT) on January 2, 2026 at a weighted average price of $28.9606 per share.
The sale of shares was executed pursuant to a 10b5-1 trading plan adopted by the reporting person on March 11, 2025, with a plan end date of May 29, 2026.
Following the reported transaction, the reporting person still holds a direct ownership of 69,744 shares of the issuer's common stock.

Other reports for Arcutis Biotherapeutics, Inc.

Current Report Quarterly Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.